Dose escalation safety and tolerance study of the N-methyl-D-aspartate antagonist dextromethorphan in neurosurgery patients

Journal of Neurosurgery

Volumn 84, Issue 5, 1996, Pages 860-866

  Steinberg, Gary K ^a   Bell, Teresa E ^a   Yenari, Midori A ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

cerebral ischemia; clinical trial; dextromethorphan; glutamate; N methyl D aspartate antagonist

Indexed keywords

DEXTROMETHORPHAN; DEXTROMETHORPHAN PLUS GUAIFENESIN; DEXTRORPHAN; GUAIFENESIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; ATAXIA; BRAIN ISCHEMIA; BRAIN SURGERY; BRAIN TUMOR; CEREBROVASCULAR DISEASE; CHILD; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROPROTECTION; NYSTAGMUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SURGICAL PATIENT; VERTIGO; VISUAL IMPAIRMENT; VOMITING;

EID: 0029876331     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.1996.84.5.0860     Document Type: Article

References (27)

1. Albers GW, Atkinson RP, Kelley RE, et al: Safety, tolerability, and pharmakokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Stroke 26:254-258, 1995
2. Albers GW, Sáenz RE, Moses J Jr. et al: Safety and tolerance of oral dextromethorphan in patients at risk for brain ischemia. Stroke 22:1075-1077, 1991
3. Albers GW, Sáenz RE, Moses JA Jr: Tolerability of oral dextromethorphan in patients with a history of brain ischemia. Clin Neurophannacol 15:509-514, 1992
4. Choi DW: Dextrorphan and dextromethorphan attenuate glutamate neurotoxicity. Brain Res 403:333-336, 1987
5. Choi DW, Maulucci-Gedde M, Kriegstein AR: Glutamate neurotoxicity in cortical cell culture. J Neurosci 7:357-368, 1987
6. Choi DW, Peters S, Viseskul V: Dextrorphan and levorphanol selectively block N-methyl-D-aspanate receptor-mediated neurotoxicity on cortical neurons. J Pharmacol Exp Ther 242: 713-720, 1987
7. George CP, Goldberg MP, Choi DW, et al: Dextromethorphan reduces neocortical ischemic neuronal damage in vivo. Brain Res 440:375-379, 1988
8. Goldberg MP, Pham PC, Choi DW: Dextrorphan and dextromethorphan attenuate hypoxic injury in neuronal culture. Neurosci Lett 80:11-15, 1987
9. Grotta J. Safety and tolerability of the glutamate antagonist CGS19755 in acute stroke patients. Stroke 25:255, 1994 (Abstract)
10. Grotta J, Clark W. Coull B, et al: Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial. Stroke 26:602-605, 1995
11. Hollander D, Pradas J, Kaplan R, et al: High-dose dextromethorphan in amyotrophic lateral sclerosis: phase I safety and pharmacokinetic studies. Ann Neurol 36:920-924, 1994
12. Lo EH, Steinberg GK, Panahian N, et al: Profiles of extracellular amino acid changes in focal cerebral ischaemia: effects of mild hypothermia. Neurol Res 15:281-287, 1993
13. Muir KW, Lees KR: Clinical experience with excitatory amino acid antagonist drugs. Stroke 26:503-513, 1995
14. Olney JW, Labruyere J, Price MT: Pathological changes induced in cerebrocortical neurons by phencycylidine and related drugs. Science 244:1360-1362, 1989
15. Prince DA, Feeser HR: Dextromethorphan protects against cerebral infarction in a rat model of hypoxia-ischemia. Neurosci Lett 85:291-296, 1988
16. Steinberg GK, Bell T: Clinical dose-escalation safety study of the NMDA antagonist, dextromethorphan in neurosurgical patients. Stroke 22:141, 1991 (Abstract)
17. Steinberg GK, George CP, DeLaPaz R, et al: Dextromethorphan protects against cerebral injury following transient focal ischemia in rabbits. Stroke 19:1112-1118, 1988
18. Steinberg GK, Kunis D, DeLaPaz R, et al: Neuroprotection following focal cerebral ischaemia with the NMDA antagonist dextromethorphan, has a favourable dose response profile. Neurol Res 15:174-180, 1993
19. Steinberg GK, Kunis D, Saleh J. et al: Protection after transient focal cerebral ischemia by the N-methyl-D-aspartate antagonist dextrorphan is dependent upon plasma and brain levels. J Cereb Blood Flow Metab 11:1015-1024, 1991
20. Steinberg GK, Lo EH, Kunis DM, et al: Dextromethorphan alters cerebral blood flow and protects against cerebral injury following focal ischemia. Neurosci Lett 133:225-228, 1991
21. Steinberg GK, Perez-Pinzon MA, Maier CM, et al: CGS 19755 (selfotel): correlation of in vitro neuroprotection, protection against experimental ischemia and CSF levels in cerebrovascular surgery patients, in Krieglstein J, Oberpichler-Schwenk H (eds): Pharmacology of Cerebral Ischemia. Stuttgart: Wissenschaftliche Verlagsgesellschaft. 1994, pp 225-232
22. Steinberg GK, Saleh J, Kunis D: Delayed treatment with dextromethorphan and dextrorphan reduces cerebral damage after transient focal ischemia. Neurosci Lett 89:193-197, 1988
23. Takagi K, Ginsberg MD, Globus MY, et al: Changes in amino acid neurotransmitters and cerebral blood flow in the ischemic penumbral region following middle cerebral artery occlusion in the rat: correlation with histopathology. J Cereb Blood Flow Metab 13:575-585, 1993
24. Tortella FC, Martin DA, Allot CP, et al: Dextromethorphan attenuates post-ischemic hypoperfusion following incomplete global ischemia in the anesthetized rat. Brain Res 482: 179-183, 1989
25. van Rijen PC, Verheul HB, van Echteld CJA, et al: Effects of dextromethorphan on rat brain during ischemia and reperfusion assessed by magnetic resonance spectroscopy. Stroke 22: 343-350, 1991
26. Walker FO, Hunt VP: An open label trial of dextromethorphan in Huntington's disease. Clin Neuropharmacol 12:322-330, 1989
27. Woodworth JR, Dennis SR, Moore L, et al: The polymorphic metabolism of dextromethorphan. J Clin Pharmacol 27: 139-143, 1987